← All stories
Markets
Enhertu wins EU approval for first-line HER2-positive breast cancer
2 outlets - including Investing and Kalkinemedia - are covering this story. AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo have received European Commission approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-po…
Covered by 2 outlets
All coverage · 2 articles
Investing.com UK
·1h ago
Enhertu wins EU approval for first-line HER2-positive breast cancer
Kalkine Media UK
·1h ago
AstraZeneca and Daiichi Sankyo Obtain EU Approval for Enhertu Plus Pertuzumab as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo have received European Commission approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-po…